NCT04894994

FLX475 in Combination With Ipilimumab in Advanced Melanoma

Phase 2 Study of FLX475 in Combination With Ipilimumab in Advanced Melanoma

• Status: Terminated
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 6 (actual)
• Sponsor: RAPT Therapeutics, Inc. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This clinical trial is a Phase 2, open-label study to determine the anti-tumor activity of FLX475 in combination with ipilimumab in subjects with advanced melanoma previously treated with an anti-programmed cell death 1 (anti-PD-1) or anti-programmed cell death ligand 1 (anti-PD-L1) agent. The study will be conducted starting with a safety run-in portion in which 6 eligible subjects will be enrolled and treated for at least one 3-week cycle to determine if the safety profile of FLX475+ipilimumab is acceptable to complete enrollment of the approximately 20-subject study.

Conditions

• Advanced Melanoma

Interventions

Type	Name	Description
DRUG	FLX475	Tablet
DRUG	Ipilimumab	IV infusion

Timeline

• Start date: 2021-09-03
• Primary completion: 2022-09-13
• Completion: 2022-09-13
• First posted: 2021-05-20
• Last updated: 2023-12-05
• Results posted: 2023-12-05

Locations

4 sites across 1 country: United States

Regulatory

• FDA-regulated drug study